BCG immunotherapy of bladder cancer: 20 years on

Lancet

Volumn 353, Issue 9165, 1999, Pages 1689-1694

  Alexandroff, Anton B ^a   Jackson, Andrew M ^b   O'Donnell, Michael A ^c   James, Keith ^a,d  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c Beth Israel Deaconess Medical Center   (United States)

^d ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

BCG VACCINATION; BLADDER CANCER; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CIGARETTE SMOKING; HUMAN; IMMUNE RESPONSE; INTRAVESICAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; TRANSITIONAL CELL CARCINOMA;

EID: 0033562695     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)07422-4     Document Type: Review

References (47)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998; 48: 6-29.
2. Wynder EL, Goldsmith R. The epidemiology of bladder cancer: a second look. Cancer 1977; 40: 1246-68.
3. Utz DC, Farrow GM. Management of carcinoma-in-situ of the bladder: the case for surgical management. Urol Clin North Am 1980; 7:533-41.
4. Pawinski A, Sylvester R, Kurth KH, et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. J Urol 1996; 156: 1934-41.
5. Lamm DL, Riggs DR, Traynelis CL, Nseyo UO. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 1995; 153: 1444-50.
6. Crispen R. History of BCG and its substrains. Prog Clin Biol Res 1989; 310: 35-50.
7. van der Meijden AP, Debruyne FM, Steerenberg PA, de Jong WH. Aspects of non-specific immunotherapy with BCG in superficial bladder cancer: an overview. Prog Clin Biol Res 1989; 310: 11-33.
8. Mathe G, Amiel JL, Schwarzenberg L, et al. Active immunothreapy for acute lymphoblastic leukaemia. Lancet 1969; i: 697-99.
9. Morales A, Edinger D, Bruce AW. Intracavity bacillus Calmette Guerin in the treatment of superficial bladder tumours. J Urol 1976; 116: 180-83.
10. Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD, Radwin HM. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol 1980; 124: 38-40.
11. Herr HW. Intravesical BCG: current results, natural history and implications for urothelial cancer prevention. J Cell Biochem 1992; 161 (suppl): 112-19.
12. Patel A, Fuchs GJ. New techniques for the administration of topical adjuvant therapy after endoscopic ablation of upper urinary tract transitional cell carcinoma. J Urol 1988; 159: 71-75.
13. Lamm DL, Steg A, Boccon-Gibog L, et al. Complications of bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications. Prog Clin Biol Res 1989; 310: 335-55.
14. O'Donnell MA, DeWolf WC. Bacillus Calmette-Guerin immunotherapy for superficial bladder cancer: new prospects for an old warhorse. Surg Oncol Clin N Am 1995; 4: 189-201.
15. O'Donnell MA, Chen X, Luo Y, DeWolf WC. Experimental and clinical evidence of enhancement of BCG efficacy by adding interferon-alpha. J Urol 1997; 157 (suppl): 383.
16. Kuroda K, Brown EJ, Telle WB, Russell DG, Ratliff TL. Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumour cells. J Clin Invest 1993; 91: 69-76.
17. Jackson AM, James K. Understanding the most successful immunotherapy for cancer. The Immunologist 1994; 2: 208-15.
18. Alexandroff AB, Robins RA, Murray A, James K. Tumour immunology: false hopes - new horizons? Immunol Today 1998; 19: 247-50.
19. Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF. Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 1992; 147: 1636-42.
20. Shapiro AW, Lijovetsky G, Pode D. Changes of the mucosal architecture and urine cytology during BCG treatment. World J Urol 1988; 6: 61-64.
21. Jackson AM, Alexandroff AB, Kelly RW, et al. Changes in urinary cytokines and soluble intercellular adhesion molecule 1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol 1995; 99: 369-75.
22. Cassatella MA. The production of cytokines by polymorphonuclear neutrophils. Immunol Today 1995; 16: 21-26.
23. Ratliff TL, Ritchey JK, Yuan JJ, Andriole GL, Catalona WJ. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 1993; 150: 1018-23.
24. Thanhauser A, Bohle A, Schneider B, et al. The induction of bacillus-Calmette-Guerin-activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immunol Immunother 1995; 40: 103-08.
25. Wang R, Rogers AM, Ratliff TL, Russell JH. CD95-dependent bystander lysis caused by CD4+ T helper 1 effectors. J Immunol 1996; 157: 2961-68.
26. Ridge PJ, Ross FD, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ helper and a T-killer cell. Nature 1998; 393: 474-78.
27. Schoenberger SP, Toes REM, van der Voort EIH, Offringa R, Melief CJM. T cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998; 393: 480-83.
28. Bennett SRM, Carbone FR, Karamalis F, Flavell RA, Miller JFAP, Heath WR. Help for cytotoxic T cell responses is mediated by CD40 signalling. Nature 1998; 393: 478-80.
29. Cui J, Shin T, Kawano T, et al. Requirement for V14 NKT cells in IL-12-mediated rejection of tumours. Science 1997; 278: 1623-26.
30. Patard JJ, Brasseur F, Gil-Diez S, et al. Expression of MAGE genes in transitional-cell carcinomas of the urinary bladder. Int J Cancer 1995; 64: 60-64.
31. Zlotta AR, Drowart A, Huygen K, et al. Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacillus Calmette-Guerin (BCG) in patients with superficial bladder cancer. Clin Exp Immunol 1997; 109: 157-65.
32. Guéguen M, Patard J, Gaugler B, et al. An antigen recognized by autologous CTLs on a human bladder carcinoma. J Immunol 1998; 160: 6188-94.
33. Dunbar R, Ogg G, Chen J, Rust N, Van der Bruggen P, Cerundoto V. Direct isolation, phenotyping and cloning of low-frequency antigen- specific cytotoxic T lymphocytes from peripheral blood. Cur Biol 1998; 8: 413-16.
34. Misra N, Murtala A, Walker B, et al. Cytokine profile of circulating T cells of leprosy patients reflects both indiscriminate and polarized T-helper subsets: T-helper phenotype is stable and uninfluenced by related antigens of mycobacterium leprae. Immunol 1995; 86: 97-103.
35. Kaempfer R, Gerez L, Farbstein H, et al. Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J Clin Oncol 1996; 14: 1778-86.
36. McAveney KM, Gomella LG, Lattime EC. Induction of TH1- and TH2-associated cytokine mRNA in mouse bladder following intravesical growth of the murine bladder tumour MB-49 and BCG immunotherapy. Cancer Immunol Immunother 1994; 39: 401-06.
37. Jackson AM, Ivshina AV, Senko O, et al. Prognosis of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndromes analysis. J Urol 1998; 159: 1054-63.
38. Alexandroff A, Jackson AM, Skibinska A, James K. Production of IL-5, a classical Th2 cytokine, following bacillus Calmette-Guerin immunotherapy of bladder cancer. Int J Oncol 1996; 9: 179-82.
39. Bohle A, Rusch-Gerdes S, Ulmer AJ, Braasch H, Jocham D. The effect of lubricants on viability of bacillus Calmette-Guerin for intravesical immunotherapy against bladder carcinoma. J Urol 1996; 155: 1892-96.
40. Ratliff TL, Ritchey JK, Brandhorst J, Hanna MG. Time-dependent aggregation of reconstituted BCG vaccine. J Urol 1994; 152: 2147-50.
41. Lamm DL, Riggs DR, Shriver JS, van Gilder PF, Rach JF, DeHaven JI. Megadose vitamins in bladder cancer: a double-blind clinical trial. J Urol 1994; 151: 21-26.
42. Haley J, Young D, Alexandroff A, James K, Jackson AM. Enhancing the immunotherapeutic potential of mycobacteria by transfection with tumour necrosis factor-α. Immunology 1999; 96: 114-21.
43. O'Donnell MA. The genetic reconstruction of BCG as a new immunotherapeutic tool. Trends Biotechnol 1997; 15: 512-17.
44. Jackson AM, Murphy M. The use of mycobacteria for the delivery of cytokines in gene therapy. Curr Res Mol Therap 1998; 1: 256-61.
45. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumour activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997; 3: 558-61.
46. Kadhim SA, Chin JL, Batislam E, Karlik SJ, Garcia B, Skamene E. Genetically regulated response to intravesical bacillus Calmette-Guerin immunotherapy of orthopic murine bladder tumour. J Urol 1997; 158: 646-52.
47. Lattime EC, Gomella LG, McCue PA. Murine bladder carcinoma cells present antigen to BCG-specific CD4+ T-cells. Cancer Res 1992; 52: 4286-90.